By Steve Joseph
Vice President, Market Development, ShareVault
Biotechnology companies rely heavily on alliances with pharmaceutical companies to finance their research and development expenditures, and pharmaceutical firms rely heavily on alliances to supplement their internal research and development.And those partnerships are a good thing: Drugs that are jointly developed are more likely to advance in clinical trials than drugs that are developed by a single company. However, inexperienced biotech companies often receive substantially discounted payments when signing their first deal.
So, how do you know what your drug candidate is worth?
Join us and thousands of health technology innovators and decision makers at the LifeScience Alley Conference on November 19, 2014. Hear from world-renowned companies, providers and payors as they discuss the policies, business practices and advancements that are reinventing healthcare. It’s in Minneapolis!
We’ll be in booth 701, so please come by and say hello.
LifeScience Alley is the largest, state-based life science association in the country. Their 690+ member organizations come from all sectors of the life sciences ecosystem. The conference, which is celebrating 30 years of groundbreaking achievement and vision into the future of healthcare, is a great place to connect with like-minded companies, share insights and expertise, collaborate and forge partnerships.
To learn more visit www.lifesciencealley.org.
By John Badger,
Co-Founder and VP of Marketing & Product, ShareVault
Based on the webinar, The Seller’s Guide to M&A HR, by Brian Moriarty, VP of MADO (Mergers, Acquisitions, Divestitures & Outsourcing), Hewlett-Packard
Smart managers on both sides of a deal know that successful mergers are not just about financial wins, but are a result of merging the intellectual capital of both organizations. This means effectively channeling the skills and enthusiasm of employees and streamlining the way in which the new business operates so that it can rapidly overcome hurdles, clearly define new roles and capitalize on synergies.
By David Mosley, Director of Sales, ShareVault
As a former institutional salesman at an investment bank, I recognize the complexity and risks associated with preparing and distributing a Private Placement Memorandum (PPM). The Private Placement Memorandum is a stand-alone document, in that it contains all the information an investor needs to make an investment decision. As such, PPMs must be drafted very carefully to ensure that they are comprehensive and do not omit any information that a reasonable person would consider relevant in making an investment decision. It’s also crucial that they not contain any information that could be considered misleading.
By Stephen Joseph, VP of Market Development, ShareVault
Based on the white paper by Linda Pullan, PhD, Pullan Consulting
Biotech companies know that it is essential to align with strategic partners to advance their drug candidates to market. To partner successfully the small biotech company must effectively play the partnering game. The process requires determining when it’s best to seek out a partner, having a defined strategy, clearly communicating how your opportunity is unique, understanding the partnering process both from your perspective and the partner’s, and then reaching out to a variety of partners in order to find one that best fits your needs.
#1 Decide When to Play
Deciding when to seek out a partnership may be largely determined by what it is you want to accomplish. The goal of partnering is typically to obtain non-dilutive funding or to offload expenses when development costs, such as Phase III trials, become too burdensome. But a partnership can also be valuable for gaining a partner’s expertise and resources, or for the validation that partnership brings to your company. Also keep in mind that a partnership will generally increase the probability of that your drug will be approved.
This week was busy in terms of global security threats. On Tuesday, Microsoft announced MS14-058, a critical security vulnerability in the kernel-mode driver that could allow remote code execution, and on the same day, Google announced its discovery of POODLE (Padding Oracle On Downloaded Legacy Encryption), a security bug in SSLv3, an encryption technology used in legacy computer systems, such as Microsoft XP Internet Explorer 6, prior to Service Pack 3.
ShareVault implemented the fix to MS14-058 on Wednesday, and a fix to POODLE was implemented on Thursday.
Some users running Windows XP with Internet Explorer 6 without service pack 3 will need to upgrade their browser in order to continue using ShareVault. This represents less than a fraction of a percent of our users. While we apologize for the inconvenience to these users, we believe that this was the right decision given the security threat posed by the POODLE vulnerability.
At ShareVault, security is a top priority, and our customers count on us to react quickly to security threats. We are very proud that our security, operations and development teams reacted rapidly to these threats and implemented quick fixes.
By John Badger, Co-Founder and VP of Marketing and Product, ShareVault
Based on the white paper by Andy Thorsen, “Preparing for Your Exit”
You’ve probably heard the saying that tech companies are generally bought, not sold. This means that you, as the seller, may have very little control over who acquires your company and, perhaps more importantly, when that acquisition takes place. Constant readiness then becomes imperative in order to both look attractive to potential buyers and to maximize the value of your company.
Download the White Paper: Preparing for Your Exit
When an exit is not on your company’s radar, certain documentation can fall through the cracks or become dated, which will be a red flag should a buyer approach your company. And, if it’s a red flag for a buyer, then it should be a red flag for you as well. If a buyer wouldn’t want to inherit your company’s liabilities, why would you want to retain them? But if being prepared for an exit is part of your company’s DNA, not only will you avoid scrambling for data during due diligence, but you’ll have data in place to inform you of your company’s health, expose weaknesses and liabilities, grow your company and increase value.